Vivesto completes recruitment in Paccal Vet study in cats
The study determined the maximum tolerated dose, with anti-tumor effects observed in 21 cats.
See the latest news and media coverage for Vivesto. We track all announcements, press releases, and industry mentions in real time, all in one place.
Swedish oncology drug development company
vivesto.comLast updated
In short: Vivesto advanced its oncology pipeline through clinical milestones, a reverse share split, and the appointment of a new CFO.
The study determined the maximum tolerated dose, with anti-tumor effects observed in 21 cats.
Topline results expected Q3 2026. The study evaluates Paccal Vet in dogs with splenic hemangiosarcoma.
The study shows Cantrixil was well tolerated intravenously in dogs, supporting development toward Phase I in AML.
He will take up the role on July 1, 2026, succeeding Robert Maiorana.
Visit a quote page and your recently viewed tickers will be displayed here.
At close: 17 April at 16:00:00 GMT-4...
At the Annual General Meeting in Vivesto AB ("Vivesto" or the "company") held on 7 May 2026, the following resolutions were passed. All resolutions were...
The Board of Directors of the research company Vivesto proposes that the Annual General Meeting on May 7 resolve on a reverse stock split, whereby...
Track Vivesto and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Vivesto and other trending companies.